Emergence of Novel Agents for Treatment of Hodgkin Lymphoma

Nahla AM Hamed
Additional contact information
Nahla AM Hamed: Department of Hematology, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2017, vol. 8, issue 3, 51-54

Abstract: cHL patients are generally classified in 1 of 3 groups: early-stage favorable, early-stage unfavorable or advanced-stage disease. Prognostication in advanced-stage patients is defined by the IPS. Patients with low-risk IPS are treated with 6 cycles of standard ABVD, whereas high-risk patients are initially treated with the more intensive German-derived regimen, escalated BEACOPP. Treatment may be further refined through PET-adapted therapy. The optimal chemotherapy for advanced stage HL can be endlessly debated. Based on recent study results, two classes of drugs stand out as highly active in advanced HL: antibody-drug conjugates (BV) and programmed death 1 inhibitors (Nivolumab). There are abundant salvage therapy options for patients with R/R HL. The choice of salvage chemotherapy therapy is becoming increasingly difficult in the era of novel agents.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555737.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555737.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:8:y:2017:i:3:p:51-54

DOI: 10.19080/CTOIJ.2017.08.555737

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().